Apeloa Pharmaceutical Co.,Ltd
000739
Classificação em ações
#4293
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Preço da ação
$3.13
Valor de mercado
$3.62B
Variação (1 dia)
-1.42%
Variação (1 ano)
46.59%
País
CN
Negociar Apeloa Pharmaceutical Co.,Ltd (000739)
Categoria
Healthcare
Receita da Apeloa Pharmaceutical Co.,Ltd (000739)
Receita em Jun 2026 TTM: $1.37B
De acordo com os últimos relatórios financeiros da Apeloa Pharmaceutical Co.,Ltd, a receita atual da empresa (TTM) é $1.37B. Em 2024, a empresa obteve uma receita de $1.65B um aumento em relação a a receita do ano 2023, que foi de $1.62B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Apeloa Pharmaceutical Co.,Ltd de 2000 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $1.37B | -1.63% |
| 2025 | $1.39B | -15.31% |
| 2024 | $1.65B | 1.61% |
| 2023 | $1.62B | 6.03% |
| 2022 | $1.53B | 8.65% |
| 2021 | $1.41B | 16.65% |
| 2020 | $1.21B | 16.48% |
| 2019 | $1.04B | 11.72% |
| 2018 | $926.93M | 8.63% |
| 2017 | $853.30M | 24.14% |
| 2016 | $687.35M | 2.89% |
| 2015 | $668.02M | -2.25% |
| 2014 | $683.37M | 7.52% |
| 2013 | $635.58M | 13.89% |
| 2012 | $558.08M | 25.04% |
| 2011 | $446.31M | 93.68% |
| 2010 | $230.44M | 15.01% |
| 2009 | $200.35M | 11.32% |
| 2008 | $179.98M | 26.18% |
| 2007 | $142.64M | -5.97% |
| 2006 | $151.70M | 18.26% |
| 2005 | $128.27M | 27.82% |
| 2004 | $100.36M | 7.83% |
| 2003 | $93.07M | 16.84% |
| 2002 | $79.66M | 364.75% |
| 2001 | $17.14M | -20.73% |
| 2000 | $21.62M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $23.54B | 1,615.38% |
DE
|
|
| $23.73B | 1,629.92% |
DE
|
|
| $29.24B | 2,031.13% |
JP
|
|
| $5.85B | 326.29% |
CH
|
|
| $6.61B | 381.89% |
IN
|
